Roundup Claim Payouts 2026: What Monsanto Settlers Are Actually Receiving
Bayer's Roundup litigation has cost the company many billions, and thousands of claimants have been paid through a points-based settlement program — but no fixed "Roundup payout amount" exists. This guide explains what settlers actually receive, how awards are calculated, and where the litigation stands in 2026.
Key facts:
- In June 2020, Bayer announced a settlement framework of $8.8 to $9.6 billion to resolve roughly 125,000 existing Roundup claims, plus $1.25 billion reserved for a future-claims class that a federal judge later rejected.
- Awards are calculated on a points system weighing NHL severity, exposure duration, age, and other factors — not a flat amount per person.
- In January 2024, a Philadelphia jury awarded $2.25 billion to John McKivison, who developed non-Hodgkin's lymphoma after Roundup use; the trial judge later reduced the award substantially.
- The EPA maintains that glyphosate is "not likely to be carcinogenic to humans," while the World Health Organization's cancer agency (IARC) classified it in 2015 as "probably carcinogenic to humans" — the scientific split at the heart of the trials.
For a visual walkthrough of topics like this one, see the Problem Solved channel on YouTube.
The $10 Billion Framework That Started It All
Non-Hodgkin's lymphoma (NHL) — a cancer of the lymphatic system — is the diagnosis at the center of virtually every Roundup claim. Plaintiffs allege that glyphosate, the active ingredient in Monsanto's Roundup weedkiller, caused their NHL after years of occupational exposure.
In June 2020, Bayer — which acquired Monsanto in 2018 — announced a sweeping deal: $8.8 to $9.6 billion for the existing inventory of claims, plus $1.25 billion earmarked for a proposed class of future NHL cases. That second piece collapsed in May 2021 when the federal judge refused to approve it, ruling it would unfairly bind future claimants. The existing-claims program moved forward, and thousands of settlements have been paid through it since.
How Settlement Awards Are Actually Calculated
Forget the standard check. The program scores each claimant on documented factors: NHL severity and subtype, exposure length and intensity, age, remission status, and documentation strength. Higher scores draw larger shares of the fund.
That is why two neighbors with the same diagnosis can receive very different amounts: a farmworker who sprayed commercially for twenty years and a weekend homeowner present fundamentally different exposure profiles. Compensation varies widely by case, and most settlements are confidential — treat published "average payout" figures from law-firm ads as marketing, not data.
What Recent Verdicts Tell Us
Outside the settlement program, trial verdicts keep making headlines — and cutting both ways. In November 2023, a Philadelphia jury awarded $175 million to Ernest Caranci, finding his NHL was linked to Roundup. Two months later, another Philadelphia jury awarded $2.25 billion to John McKivison, though the judge later slashed it, as routinely happens with outsized punitive awards. In March 2025, a Georgia jury added a $2.1 billion verdict to the plaintiffs' column.
Bayer has also won its share of trials and keeps appealing plaintiff wins. The takeaway: juries remain deeply divided, verdicts volatile, neither side owning the momentum.
Who Benefits From This — and Who Does Not
Agricultural workers and landscapers with an NHL diagnosis are the core beneficiaries. Years of professional mixing, spraying, or working around Roundup create the strongest exposure documentation and the clearest fit with the program's scoring. If that describes you, see our guide to choosing a Roundup attorney.
Homeowners with heavy, long-term Roundup use and an NHL diagnosis can also qualify. Weekend gardeners with decades of documented use have recovered through the program, though their exposure scores — and awards — run lower than occupational users'.
Who does not benefit? Anyone without a qualifying NHL diagnosis has no claim; exposure alone, however heavy, is not compensable. Other cancers fall outside the program's criteria. And claimants who cannot document their Roundup use — no employer records, no purchase history, no credible testimony — face an uphill battle even with a valid diagnosis.
Where New Claims Stand in 2026
The 2020 framework covered claims from that era, but the litigation continues: Bayer keeps settling newly filed cases individually while fighting others at trial, and new lawsuits are still filed in state courts — California remains an active venue, as our overview of Roundup counsel in California explains.
There is no open class action to join and no program-wide claims deadline running. Each case is evaluated on its own facts — so documentation quality matters more than ever.
The Glyphosate Question: Why Science and Courts Disagree
The litigation's strangest feature: regulators and juries look at the same chemical and reach opposite conclusions. The EPA's position, reaffirmed in its interim review, is that glyphosate is "not likely to be carcinogenic to humans" when used as directed. The WHO's cancer agency (IARC), by contrast, classified it as "probably carcinogenic to humans" in 2015, citing occupational-exposure studies.
Bayer also responded commercially: in 2023 it removed glyphosate from U.S. residential Roundup products — described as risk management, not an admission. Agricultural formulations, used by most claimants, still contain it.
Frequently Asked Questions
Who benefits from the Roundup settlement program?
People diagnosed with non-Hodgkin's lymphoma after substantial Roundup exposure — especially farmworkers, landscapers, and groundskeepers with years of documented occupational use. Homeowners with long-term, heavy residential use and an NHL diagnosis can also qualify.
Who is not eligible for a Roundup claim?
Anyone without a non-Hodgkin's lymphoma diagnosis is not eligible, regardless of exposure. Other cancers, or exposure alone without illness, do not fit the program's criteria — and undocumented exposure claims are very difficult to win.
How do I start a Roundup claim?
The concrete steps: 1) obtain medical records confirming your NHL diagnosis and subtype; 2) document exposure — employer records, receipts, container photos, a timeline; 3) note your state's filing deadline; 4) have a Roundup-experienced firm evaluate your case, free and on contingency; 5) let counsel file and negotiate — do not contact Bayer or sign anything alone.
What determines how much I would receive?
A points-based formula: NHL severity and subtype, exposure duration and intensity, age, treatment history, documentation quality. No flat amount exists. Compensation varies widely by case, and most settlements are confidential.
Is Roundup still sold?
Yes, but the residential U.S. product dropped glyphosate in 2023. Agricultural and professional formulations still contain it, and the litigation concerns historic and ongoing exposure to the glyphosate-based product.
Disclaimer: This article is for general information only and is not legal advice. Consult a qualified professional for advice about your situation.